Skip to main content

Advertisement

SpringerLink
Log in

Depression and glioblastoma, complicated concomitant diseases: a systemic review of published literature

  • Review
  • Published:
Neurosurgical Review Aims and scope Submit manuscript

Abstract

Glioblastoma multiforme (GBM) is the most common primary brain cancer. Depression is a common co-morbidity of this condition. Despite this common interaction, relatively little research has been performed on the development of GBM-associated depression. We performed a literary search of the PubMed database for articles published relating to GBM and depression. A total of 85 articles were identified with 46 meeting inclusion criteria. Depression significantly impacts care, decreasing medication compliance, and patient survival. Diagnostically, because depression and GBM share intricate neuro-connectivity in a way that effect functionality, these diseases can be mistaken for alternative psychological or pathological disorders, complicating care. Therapeutically, anti-depressants have anti-tumor properties; yet, some have been shown to interfere with GBM treatment. One reason for this is that the pathophysiological development of depression and GBM share several pathways including altered regulation of the 5-HT receptor, norepinephrine, and 3′:5′-cyclic monophosphate. Over time, depression can persist after GBM treatment, affecting patient quality of life. Together, depression and GBM are complicated concomitant diseases. Clinicians must be aware of their co-existence. Because of overlapping molecular pathways involved in both diseases, careful medication selection is imperative to avoid potential adverse interactions. Since GBMs are the most common primary brain cancer, physicians dealing with this disease should be prepared for the development of depression as a potential sequela of this condition, given the related pathophysiology and the known poor outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee ShU (2017) Glioblastoma Multiforme: of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev 18(1):3–9

    PubMed  PubMed Central  Google Scholar 

  2. Robles P, Fiest KM, Frolkis AD (2015) The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro-Oncology 17(6):776–783

    Article  PubMed  Google Scholar 

  3. Nizamutdinov D et al (2017) Survival Outcomes Prognostication in Glioblastoma Diagnosed Patients. World Neurosurg S1878–S8750

  4. Iaccarino C, Orlandi E, Ruggeri F, Nicoli D, Torricelli F, Maggi M, Cerasti D, Pisanello A, Pedrazzi G, Froio E, Crafa P, D'Abbiero N, Michiara M, Ghadirpour R, Servadei F (2015) Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy. Clin Neurol Neurosurg 132:1–8

    Article  PubMed  Google Scholar 

  5. Villani V, Casini B, Pace A (2015) The prognostic value of pyrosequencing-detected MGMT promoter Hypermethylation in newly diagnosed patients with glioblastoma. Dis Markers 2015:1–6

    Article  CAS  Google Scholar 

  6. Yuan Y, Zhang H, Liu X (2017) MicroRNA signatures predict prognosis of patients with glioblastoma multiforme through the Cancer genome atlas. Oncotarget 8(35):58386–58393

    PubMed  PubMed Central  Google Scholar 

  7. Wang J, Mugge L et al (2017) Current therapies and future directions in treatment of glioblastoma, in advances in biology and treatment of glioblastoma Springer Chapter, p 57–90

  8. Dai X, Faber JE (2010) Endothelial nitric oxide synthase deficiency causes collateral vessel rarefaction and impairs activation of a cell cycle gene network during arteriogenesis. Circ Res 106(12):1870–1881

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62(6):617–627

    Article  PubMed  PubMed Central  Google Scholar 

  10. Song YM, Lee K, Sung J (2017) Genetic and environmental relationships between eating behavior and symptoms of anxiety and depression. Eat Weight Disord. https://doi.org/10.1007/s40519-017-0445-2

  11. Wolniczak I et al (2017) Fruits and vegetables consumption and depressive symptoms: a population-based study in Peru. PLoS One 12(10):e0186379

  12. Bornovalova MA et al (2017) Genetic and environmental influences on the codevelopment among borderline personality disorder traits, major depression symptoms, and substance use disorder symptoms from adolescence to young adulthood. Dev Psychopathol 19(1):1–17

    Google Scholar 

  13. Edwards AC et al (2017) Polygenic risk for severe psychopathology among Europeans is associated with major depressive disorder in Han Chinese women. Psychol Med 3:1–13

    Google Scholar 

  14. Schumann L et al (2017) Persistence and innovation effects in genetic and environmental factors in negative emotionality during infancy: a twin study. PLoS OneTumour-associated microglia/macrophages 12(4): e0176601

  15. Spindola LM, Pan PM, Moretti PN, Ota VK, Santoro ML, Cogo-Moreira H, Gadelha A, Salum G, Manfro GG, Mari JJ, Brentani H, Grassi-Oliveira R, Brietzke E, Miguel EC, Rohde LA, Sato JR, Bressan RA, Belangero SI (2017) Gene expression in blood of children and adolescents: mediation between childhood maltreatment and major depressive disorder. J Psychiatr Res 92:24–30

    Article  PubMed  Google Scholar 

  16. Zdanowicz N, Reynaert C, Jacques D, Lepiece B, Dubois T (2017) Selective serotonergic (SSRI) versus noradrenergic (SNRI) reuptake inhibitors with and without acetylsalicylic acid in major depressive disorder. Psychiatr Danub 29:270–273

    CAS  PubMed  Google Scholar 

  17. Aznar-Lou I et al (2017) Impact of initial medication non-adherence to SSRIs on medical visits and sick leaves. J Affect Disord 226:282–286

    Article  PubMed  Google Scholar 

  18. Kim YK, Shin C (2018) The microbiota-gut-brain Axis in neuropsychiatric disorders: pathophysiological mechanisms and novel treatments. Curr Neuropharmacol 16(5):559–573

  19. Renn BN, Areán PA (2017) Psychosocial treatment options for major depressive disorder in older adults. Curr Treat Options Psychiatry 4(1):1–12

    Article  PubMed  PubMed Central  Google Scholar 

  20. Sloan E, Hall K, Moulding R, Bryce S, Mildred H, Staiger PK (2017) Emotion regulation as a transdiagnostic treatment construct across anxiety, depression, substance, eating and borderline personality disorders: a systematic review. Clin Psychol Rev 57:141–163

    Article  PubMed  Google Scholar 

  21. Almeida Macêdo E, Appenzeller S, Lavras Costallat LT (2017) Assessment of the Hospital Anxiety and Depression Scale (HADS) performance for the diagnosis of anxiety in patients with systemic lupus erythematosus. Rheumatol Int 37(12):1999–2004

  22. Lofgren SM, Nakasujja N, Boulware DR (2018) Systematic review of interventions for depression for people living with HIV in Africa. AIDS Behav 22(1):1–8

  23. Szpunar MJ, Parry BL (2018) A systematic review of cortisol, thyroid-stimulating hormone, and prolactin in peripartum women with major depression. Arch Womens Ment Health 21(2):149–161

  24. Brozek P et al (2017) Depression, sleep disturbances and anxiety in patients with relapsing-remitting multiple sclerosis: a longitudinal cohort observation. Psychiatr Danub 29:464–468

    PubMed  Google Scholar 

  25. Guekht A (2017) Epilepsy, comorbidities and treatments. Curr Pharm Des 23(37):5702–5726

  26. Wan-Fei K, Syed Hassan ST, Munn Sann L, Fadhilah Ismail SI, Abdul Raman R, Ibrahim F (2017) Depression, anxiety and quality of life in stroke survivors and their family caregivers: a pilot study using an actor/partner interdependence model. Electron Physician 9(8):4924–4933

    Article  PubMed  PubMed Central  Google Scholar 

  27. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, Meader N (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 12(2):160–174

    Article  PubMed  Google Scholar 

  28. Bortolato B et al (2016) Depression in cancer: the many biobehavioral pathways driving tumor progression. Cancer Treat Rev 52(1):58–70

    PubMed  Google Scholar 

  29. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):1006–1012

    Article  PubMed  Google Scholar 

  30. Heaven RC (1956) Psychotic depression due to cerebral gliomas; report of case. Bull Los Angel Neurol Soc 21(2):98–101

    CAS  Google Scholar 

  31. Gleason JF Jr, Case D, Rapp SR et al (2007) Symptom clusters in patients with newly-diagnosed brain tumors. J Support Oncol 5(9):427–433

    PubMed  Google Scholar 

  32. Madhusoodanan S, Ting MB, Farah T, Ugur U (2015) Psychiatric aspects of brain tumors: a review. World J Psychiatry 5(3):273–285

    Article  PubMed  PubMed Central  Google Scholar 

  33. Wellisch DK, Kaleita TA, Freeman D, Cloughesy T, Goldman J (2002) Predicting major depression in brain tumor patients. Psychooncology 11(3):230–238

    Article  PubMed  Google Scholar 

  34. Edelstein K, Coate L, Massey C, Jewitt NC, Mason WP, Devins GM (2016) Illness intrusiveness and subjective well-being in patients with glioblastoma. J Neuro-Oncol 126(1):127–135

    Article  Google Scholar 

  35. Seddighi A et al (2015) Psychological aspects in brain tumor patients: a prospective study. Hell J Nucl Med 1:63–67

    Google Scholar 

  36. Litofsky NS, Farace E, Anderson F Jr, Meyers CA, Huang W, Laws ER Jr, Glioma Outcomes Project Investigators (2004) Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery 54(2):358–366

    Article  PubMed  Google Scholar 

  37. Uribe VM (1986) Psychiatric symptoms and brain tumor. Am Fam Physician 34(2):95–98

    CAS  PubMed  Google Scholar 

  38. Noll KR, Bradshaw ME, Weinberg JS, Wefel JS (2017) Relationships between neurocognitive functioning, mood, and quality of life in patients with temporal lobe glioma. Psychooncology 26(5):617–624

    Article  PubMed  Google Scholar 

  39. Bosma I, Vos MJ, Heimans JJ, Taphoorn MJ, Aaronson NK, Postma TJ, van der Ploeg H, Muller M, Vandertop WP, Slotman BJ, Klein M (2006) The course of neurocognitive functioning in high-grade glioma patients. Neuro-Oncology 9(1):53–62

    Article  PubMed  Google Scholar 

  40. Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WKA, Brada M, Newlands E (1997) Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neuro-Oncol 34(3):263–278

    Article  CAS  Google Scholar 

  41. Kaplan CP, Miner ME (1997) Anxiety and depression in elderly patients receiving treatment for cerebral tumours. Brain Inj 11(2):129–135

    Article  CAS  PubMed  Google Scholar 

  42. Hendrix P et al (2017) Neurocognitive status in patients with newly-diagnosed brain tumors in good neurological condition: The impact of tumor type, volume, and location. Clin Neurol Neurosurg 156:55–62

    Article  PubMed  Google Scholar 

  43. Clyde Z, Chataway SJ, Signorini D, Gregor A, Grant R (1998) Significant change in tests of neurological impairment in patients with brain tumours. J Neuro-Oncol 39(1):81–90

    Article  CAS  Google Scholar 

  44. Grant R, Slattery J, Gregor A, Whittle IR (1994) Recording neurological impairment in clinical trials of glioma. J Neuro-Oncol 19(1):37–49

    Article  CAS  Google Scholar 

  45. Rooney AG, McNamara S, Mackinnon M, Fraser M, Rampling R, Carson A, Grant R (2013) Screening for major depressive disorder in adults with cerebral glioma: an initial validation of 3 self-report instruments. Neuro-Oncology 15(1):122–129

    Article  PubMed  Google Scholar 

  46. Moise D, Madhusoodanan S (2006) Psychiatric symptoms associated with brain tumors: a clinical enigma. CNS Spectr 11(1):28–31

    Article  PubMed  Google Scholar 

  47. Yapıcı-Eser H et al. (2016) Rare case of glioblastoma multiforme located in posterior corpus callosum presenting with depressive symptoms and visual memory deficits. BMJ Case Rep

  48. Cheema FA, Badr A, Iqbal J (2010) Glioblastoma multiforme presenting as treatment-resistant depression. J Clin Neurosci 22(1):123.E26

  49. Sanli AM, Turkoglu E, Dolgun H, Sekerci Z (2010) Unusual manifestations of primary glioblastoma Multiforme: a report of three cases. Surg Neurol Int 1:87

    Article  PubMed  PubMed Central  Google Scholar 

  50. Bunevicius A, Deltuva VP, Deltuviene D, Tamasauskas A, Bunevicius R (2008) Brain lesions manifesting as psychiatric disorders: eight cases. CNS Spectr 13(11):950–958

    Article  PubMed  Google Scholar 

  51. Habermeyer B, Weiland M, Mager R, Wiesbeck GA, Wurst FM (2007) A clinical lesson: glioblastoma multiforme masquerading as depression in a chronic alcoholic. Alcohol 43(1):31–33

    Article  CAS  Google Scholar 

  52. Bhattacharyya R, Sanyal D, Mukherjee B (2009) Cerebral malignancy presenting with post stroke depression. Psychiatr Q 80(3):191–197

    Article  PubMed  Google Scholar 

  53. Parekh P et al (2013) Seizure as an initial presentation of human immunodeficiency virus: acute toxoplasmosis mimicking glioblastoma multiforme. BMJ Case Rep 2013:bcr2013200795

  54. Cunha BA, Talmasov D, Connolly JJ (2014) Herpes simplex virus (HSV-1) encephalitis mimicking glioblastoma: case report and review of the literature. J Clin Med 3(4):1392–1401

    Article  PubMed  PubMed Central  Google Scholar 

  55. Linkous AG, Yazlovitskaya EM (2011) Angiogenesis in glioblastoma multiforme: navigating the maze. Anti Cancer Agents Med Chem. 11(8):712–8

  56. Sørensen MD et al (2018) Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype. Neuropathol Appl Neurobiol 44(2):185–206

  57. Urbańska K, Sokołowska J, Szmidt M, Sysa P (2014) Glioblastoma multiforme-an overview. Contemp Oncol 18(5):307–312

    Google Scholar 

  58. Baune BT, Brignone M, Larsen KG (2018) A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int J Neuropsychopharmacol 21(2):97–107

  59. Roose SP (2001) Depression, anxiety, and the cardiovascular system: the psychiatrist's perspective. J Clin Psychiatry 62(8):19–22

    PubMed  Google Scholar 

  60. Zdanowicz N, Reynaert C, Jacques D, Dubois T (2017) Depression and immunity: a psychosomatic unit. Psychiatr Danub 29:274–278

    CAS  PubMed  Google Scholar 

  61. Cloughesy TF, Cavenee WK, Mischel PS (2014) Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 9:1–25

    Article  CAS  PubMed  Google Scholar 

  62. Manji HK, Drevets WC, Charney DS (2001) The cellular neurobiology of depression. Nat Med 7(5):541–547

    Article  CAS  PubMed  Google Scholar 

  63. Cho S, Park C, Na D (2017) High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients. Exp Mol Med 49(4):e317

  64. Soomro SH, Ting LR, Qing YY, Ren M (2017) Molecular biology of glioblastoma: classification and mutational locations. J Pak Med Assoc 67(9):1410–1414

    PubMed  Google Scholar 

  65. Touat M, Idbaih A, Sanson M, Ligon KL (2017) Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol 28(7):1457–1472

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455(7215):894–902

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Lapmanee S et al (2017) Agomelatine, venlafaxine, and running exercise effectively prevent anxiety-and depression-like behaviors and memory impairment in restraint stressed rats. PLoS One 12(11):e0187671

  68. Pittenger C, Duman RS (2008) Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33(1):88–109

    Article  CAS  PubMed  Google Scholar 

  69. Yang B, Qin J, Nie Y, Li Y, Chen Q (2017) Brain-derived neurotrophic factor propeptide inhibits proliferation and induces apoptosis in C6 glioma cells. Neuroreport 28(12):726–730

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Xiong J et al (2015) Mature brain-derived neurotrophic factor and its receptor TrkB are upregulated in human glioma tissues. Oncol Lett 10(1):223–227

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Taliaz D, Stall N, Dar DE, Zangen A (2010) Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis. Mol Psychiatry 15(1):80–92

    Article  CAS  PubMed  Google Scholar 

  72. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU (1992) Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52(16):4550–4553

    CAS  PubMed  Google Scholar 

  73. Nduom EK, Wei J, Yaghi NK (2016) PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology 18(2):195–205

    Article  CAS  PubMed  Google Scholar 

  74. Sehgal A et al (1998) CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J Surg Oncol 69(2):99–104

    Article  CAS  PubMed  Google Scholar 

  75. Yamada SM, Yamaguchi F, Brown R, Berger MS, Morrison RS (1999) Suppression of glioblastoma cell growth following antisense oligonucleotide-mediated inhibition of fibroblast growth factor receptor expression. Glia 28(1):66–76

    Article  CAS  PubMed  Google Scholar 

  76. He J, Zhang W, Liu S (2017) Activation of β-adrenergic receptor promotes cellular proliferation in human glioblastoma. Oncol Lett 14(3):3846–3852

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Yang W, Wang Q, Kanes SJ, Murray JM, Nishikura K (2004) Altered RNA editing of serotonin 5-HT2C receptor induced by interferon: implications for depression associated with cytokine therapy. Brain Res Mol Brain Res 124(1):70–78

    Article  CAS  PubMed  Google Scholar 

  78. Clark RB, Perkins JP (1971) Regulation of Adenosine 3′:5′-Cyclic Monophosphate Concentration in Cultured Human Astrocytoma Cells by Catecholamines and Histamine. Proc Natl Acad Sci U S A 68(11):2757–2760

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Nautiyal KM, Hen R (2017) Serotonin receptors in depression: from A to B. F1000Research 6:123

  80. Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, el Yacoubi M, Vaugeois JM, Nomikos GG, Greengard P (2006) Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 311(5757):77–80

    Article  CAS  PubMed  Google Scholar 

  81. Wang L et al (2016) Serotonin-1A receptor alterations in depression: a meta-analysis of molecular imaging studies. BMC Psychiatry 116(1):319

  82. Liu J, Clough SJ, Dubocovich ML (2017) Role of the MT1 and MT2 melatonin receptors in mediating depressive-and anxiety-like behaviors in C3H/HeN mice. Genes Brain Behav 16(5):546–553

    Article  CAS  PubMed  Google Scholar 

  83. Ridder S, Chourbaji S, Hellweg R, Urani A, Zacher C, Schmid W, Zink M, Hörtnagl H, Flor H, Henn FA, Schütz G, Gass P (2005) Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions. J Neurosci 25(26):6243–6250

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Fioretti B, Catacuzzeno L, Sforna L, Aiello F, Pagani F, Ragozzino D, Castigli E, Franciolini F (2009) Histamine hyperpolarizes human glioblastoma cells by activating the intermediate-conductance Ca2+−activated K+ channel. Am J Phys Cell Physiol 297(1):C102–C110

    Article  CAS  Google Scholar 

  85. Li J, Zhu S, Kozono D (2014) Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget 5(4):882–893

    Article  PubMed  PubMed Central  Google Scholar 

  86. Newburgh RW, Rosenberg RN (1972) Effect of norepinephrine on glucose metabolism in glioblastoma and neuroblastoma cells in cell culture. Proc Natl Acad Sci U S A 69(7):1677–1680

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Sturzu A, Sheikh S, Klose U, Echner H, Kalbacher H, Deeg M, Nägele T, Horger M, Ernemann U, Heckl S (2012) Using the neurotransmitter serotonin to target imaging agents to glioblastoma cells. Investig New Drugs 30(6):2141–2147

    Article  CAS  Google Scholar 

  88. Cowen PJ, Browning M (2015) What has serotonin to do with depression? World Psychiatry 14(2):158–160

    Article  PubMed  PubMed Central  Google Scholar 

  89. Saldanha D, Kumar N, Ryali VSSR, Srivastava K, Pawar AA (2009) Serum serotonin abnormality in depression. Med J Armed Forces India 65(2):108–112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Choudary PV, Molnar M, Evans SJ (2005) Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A 102(43):15653–15658

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Frazer A (2000) Norepinephrine involvement in antidepressant action. J Clin Psychiatry 10:25–30

    Google Scholar 

  92. Nestler EJ, Carlezon WA (2006) The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59(12):1151–1159

    Article  CAS  PubMed  Google Scholar 

  93. Werner FM, Coveñas R (2010) Classical neurotransmitters and neuropeptides involved in major depression: a review. Int J Neurosci 120(7):455–470

    Article  CAS  PubMed  Google Scholar 

  94. Laoutidis ZG, Mathiak K (2013) Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry 13:140

  95. Steingart AB, Cotterchio M (1995) Do antidepressants cause, promote, or inhibit cancers? J Clin Epidemiol 48(11):1407–1412

    Article  CAS  PubMed  Google Scholar 

  96. Boursi B et al (2018) Chronic therapy with selective serotonin reuptake inhibitors and survival in newly diagnosed cancer patients. Eur J Cancer Care 27(1). https://doi.org/10.1111/ecc.12666

  97. Pezzella G, Moslinger-Gehmayr R, Contu A (2001) Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 70(1):1–10

    Article  CAS  PubMed  Google Scholar 

  98. Caudill JS, Brown PD, Cerhan JH, Rummans TA (2011) Selective serotonin reuptake inhibitors, glioblastoma multiforme, and impact on toxicities and overall survival: the mayo clinic experience. Am J Clin Oncol 34(4):385–387

    Article  CAS  PubMed  Google Scholar 

  99. Rooney A, Grant R (2012) SSRIs may (or may not) be a safe treatment for depression in GBM. Am J Clin Oncol 35(1):100

  100. Phillips C (2017) Brain-derived neurotrophic factor, depression, and physical activity: making the Neuroplastic connection. Neural Plast 2017:1–17

    Google Scholar 

  101. Djalali S, Holtje M, Grosse G, Rothe T, Stroh T, Grosse J, Deng DR, Hellweg R, Grantyn R, Hortnagl H, Ahnert-Hilger G (2005) Effects of brain-derived neurotrophic factor (BDNF) on glial cells and serotonergic neurones during development. J Neurochem 92(3):616–627

    Article  CAS  PubMed  Google Scholar 

  102. Arumugam V, John VS, Augustine N, Jacob T, Joy SM, Sen S, Sen T (2017) The impact of antidepressant treatment on brain-derived neurotrophic factor level: an evidence-based approach through systematic review and meta-analysis. Indian J Pharmcol 49(3):236–242

    Article  CAS  Google Scholar 

  103. Hayashi K, Michiue H, Yamada H, Takata K, Nakayama H, Wei FY, Fujimura A, Tazawa H, Asai A, Ogo N, Miyachi H, Nishiki TI, Tomizawa K, Takei K, Matsui H (2016) Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin polymerization. Sci Rep 6:23372

  104. Apaydin EA et al (2016) A systematic review of St. Johns wort for major depressive disorder. Syst Rev 5(1):148

  105. Maher AR et al (2016) St. John's Wort for major depressive disorder: a systematic review. Rand Health Q 5(4):12

  106. Ng QX, Venkatanarayanan N, Ho CY (2017) Clinical use of Hypericum perforatum (St John's wort) in depression: a meta-analysis. J Affect Disord 210:211–221

    Article  CAS  PubMed  Google Scholar 

  107. Ritz R, Daniels R, Noell S, Feigl GC, Schmidt V, Bornemann A, Ramina K, Mayer D, Dietz K, Strauss WSL, Tatagiba M (2012) Hypericin for visualization of high grade gliomas: first clinical experience. Eur J Surg Oncol 38(4):352–360

    Article  CAS  PubMed  Google Scholar 

  108. Hostanska K, Reichling J, Bommer S, Weber M, Saller R (2002) Aqueous ethanolic extract of St. John's wort (Hypericum perforatum L.) induces growth inhibition and apoptosis in human malignant cells in vitro. Pharmazie 57(5):323–331

    CAS  PubMed  Google Scholar 

  109. Jakobs D, Hage-Hülsmann A, Prenner L, Kolb C, Weiser D, Häberlein H (2013) Downregulation of β1-adrenergic receptors in rat C6 glioblastoma cells by hyperforin and hyperoside from St John's wort. J Pharm Pharmacol 65(6):907–915

    Article  CAS  PubMed  Google Scholar 

  110. Dror N, Mandel M, Lavie G (2013) Unique anti-glioblastoma activities of hypericin are at the crossroad of biochemical and epigenetic events and culminate in tumor cell differentiation. PLoS One 8(9):e73625

  111. Bielecka-Wajdman AM, Lesiak M, Ludyga T, Sieroń A, Obuchowicz E (2017) Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme. Cancer Chemother Pharmacol 79(6):1249–1256

    Article  CAS  PubMed  Google Scholar 

  112. Jeon SH, Kim SH, Kim Y, Kim YS, Lim Y, Lee YH, Shin SY (2011) The tricyclic antidepressant imipramine induces autophagic cell death in U-87MG glioma cells. Biochem Biophys Res Commun 413(2):311–317

    Article  CAS  PubMed  Google Scholar 

  113. Ramezani S, Vousooghi N, Kapourchali FR, Hadjighasem M, Hayat P, Amini N, Joghataei MT (2017) Rolipram potentiates bevacizumab-induced cell death in human glioblastoma stem-like cells. Life Sci 173:11–19

    Article  CAS  PubMed  Google Scholar 

  114. Schmidt L, Baskaran S, Johansson P, Padhan N, Matuszewski D, Green LC, Elfineh L, Wee S, Häggblad M, Martens U, Westermark B, Forsberg-Nilsson K, Uhrbom L, Claesson-Welsh L, Andäng M, Sintorn IM, Lundgren B, Lönnstedt I, Krona C, Nelander S (2016) Case-specific potentiation of glioblastoma drugs by pterostilbene. Oncotarget 7(45):73200–73215

    Article  PubMed  PubMed Central  Google Scholar 

  115. Yuhas Y, Ashkenazi S, Berent E, Weizman A (2015) Immunomodulatory activity of ketamine in human astroglial A172 cells: possible relevance to its rapid antidepressant activity. J Neuroimmunol 282:33–38

    Article  CAS  PubMed  Google Scholar 

  116. Yuhas Y, Ashkenazi S, Berent E, Weizman A (2017) Ketamine upregulates eNOS expression in human astroglial A172 cells: possible role in its antidepressive properties. J Neuroimmunol 305:75–81

    Article  CAS  PubMed  Google Scholar 

  117. Weitzner MA, Meyers CA, Valentine AD (1995) Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatr Clin Neurosci 7(3):347–350

    Article  CAS  Google Scholar 

  118. Fischer CE (2004) Experience of electroconvulsive therapy in a case of glioblastoma multiforme. Psychiatry Clin Neurosci 58(6):671

    Article  PubMed  Google Scholar 

  119. Bielecka AM, Obuchowicz E (2017) Antidepressant drugs can modify cytotoxic action of temozolomide. Eur J Cancer Care 26(5). https://doi.org/10.1111/ecc.12551

  120. Rooney A, Grant R (2013) Pharmacological treatment of depression in patients with a primary brain tumour. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006932.pub2

  121. Goldzweig G, Andritsch E, Hubert A, Brenner B, Walach N, Perry S, Baider L (2010) Psychological distress among male patients and male spouses: what do oncologists need to know? Ann Oncol 21(4):877–883

    Article  CAS  PubMed  Google Scholar 

  122. Parker PA, Baile WF, Moor C, Cohen L (2003) Psychosocial and demographic predictors of quality of life in a large sample of cancer patients. Pyschooncology 12(2):183–193

    Article  Google Scholar 

  123. Aizer AA, Chen MH, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, Graham PL, Choueiri TK, Hoffman KE, Martin NE, Hu JC, Nguyen PL (2013) Marital status and survival in patients with Cancer. J Clin Oncol 31(31):3869–3876

    Article  PubMed  PubMed Central  Google Scholar 

  124. Galvin A et al (2018) Sociodemographic, socioeconomic, and clinical determinants of survival in patients with cancer: a systematic review of the literature focused on the elderly. J Geriatr Oncol 9(1):6–14

  125. Lai H, Lai S, Krongrad A, Trapido E, Page JB, McCoy CB (1999) The effect of marital status on survival in late-stage cancer patients: an analysis based on surveillance, epidemiology, and end results (SEER) data, in the United States. Int J Behav Med 6(2):150–176

    Article  CAS  PubMed  Google Scholar 

  126. Pinquart M, Duberstein PR (2010) Associations of social networks with cancer mortality: a meta-analysis. Crit Rev Oncol Hematol 75(2):122–137

    Article  PubMed  Google Scholar 

  127. Chang SM, Barker FG (2005) Marital status, treatment, and survival in patients with glioblastoma multiforme: a population based study. Cancer 104(9):1975–1984

    Article  PubMed  Google Scholar 

  128. Wrensch M et al (2006) Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. Neurooncology 8(1):12–26

    Google Scholar 

  129. Putz F, Putz T, Goerig N, Knippen S, Gryc T, Eyüpoglu I, Rössler K, Semrau S, Lettmaier S, Fietkau R (2016) Improved survival for elderly married glioblastoma patients. Strahlenther Onkol Nov 192(11):797–805

    Article  Google Scholar 

  130. Berry DL et al (2015) Partridge adherence to oral cancer therapy: relationships with symptom distress, depression, and personal characteristics. Patient Prefer Adherence 1(9):1587–1592

    Article  Google Scholar 

  131. Hahn CA, Dunn RH, Logue PE, King JH, Edwards CL, Halperin EC (2003) Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Int J Radiat Oncol Biol Phys 55(4):992–999

    Article  CAS  PubMed  Google Scholar 

  132. Andrewes HE, Drummond KJ, Rosenthal M, Bucknill A, Andrewes DG (2013) Awareness of psychological and relationship problems amongst brain tumour patients and its association with carer distress. Psychooncology 22(10):2200–2205

    PubMed  Google Scholar 

  133. Diamond EL et al (2017) Prognostic awareness, prognostic communication, and cognitive function in patients with malignant glioma. Neurooncology 19(11):1532–1541

    Google Scholar 

  134. Flechl B, Ackerl M, Sax C, Oberndorfer S, Calabek B, Sizoo E, Reijneveld J, Crevenna R, Keilani M, Gaiger A, Dieckmann K, Preusser M, Taphoorn MJB, Marosi C (2013) The caregivers' perspective on the end-of-life phase of glioblastoma patients. J Neuro-Oncol 112(3):403–411

    Article  Google Scholar 

  135. Dauphinot V et al (2016) Risk factors of caregiver burden evolution, for patients with subjective cognitive decline or neurocognitive disorders: analysis. Journal of the American medical directors association. J Am Med Dir Assoc 17(11):1037–1043

    Article  PubMed  Google Scholar 

  136. Voltz R, Borasio GD (1997) Palliative therapy in the terminal stage of neurological disease. J Neurol. 4:S2–10

  137. Boele FW, Given CW, Given BA, Donovan HS, Schulz R, Weimer JM, Drappatz J, Lieberman FS, Sherwood PR (2017) Family caregivers' level of mastery predicts survival of patients with glioblastoma: a preliminary report. Cancer 123(5):832–840

    Article  CAS  PubMed  Google Scholar 

  138. Byer L, Kline C, Mueller S (2016) Clinical trials in pediatric neuro-oncology: what is missing and how we can improve. CNS Oncol 5(4):233–239

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Giovagnoli AR, Meneses RF, Silvani A, Milanesi I, Fariselli L, Salmaggi A, Boiardi A (2014) Quality of life and brain tumors: what beyond the clinical burden? Neurol 261(5):894–904

    Article  CAS  Google Scholar 

  140. Lucchiari C, Botturi A, Silvani A, Lamperti E, Gaviani P, Innocenti A, Finocchiaro CY, Masiero M, Pravettoni G (2015) Cognitive strategies and quality of life of patients with high-grade glioma. Support Care Cancer 23(12):3427–3435

    Article  CAS  PubMed  Google Scholar 

  141. Valko PO, Siddique A, Linsenmeier C, Zaugg K, Held U, Hofer S (2015) Prevalence and predictors of fatigue in glioblastoma: a prospective study. Neuro-Oncology 17(2):274–281

    Article  CAS  PubMed  Google Scholar 

  142. Solanki C, Sadana D, Arimappamagan A, Rao KVLN, Rajeswaran J, Subbakrishna DK, Santosh V, Pandey P (2017) Impairments in quality of life and cognitive functions in long-term survivors of glioblastoma. J Neurosci Rural Pract 8(2):228–235

    Article  PubMed  PubMed Central  Google Scholar 

  143. Steinbach JP, Blaicher HP, Herrlinger U, Wick W, Nagele T, Meyermann R, Tatagiba M, Bamberg M, Dichgans J, Karnath HO, Weller M (2006) Surviving glioblastoma for more than 5 years: the patient's perspective. Neurology 66(2):239–242

    Article  CAS  PubMed  Google Scholar 

  144. Schmidinger M, Linzmayer L, Becherer A, Fazeny-Doemer B, Fakhrai N, Prayer D, Killer M, Ungersboeck K, Dieckmann K, Marosi C (2003) Psychometric-and quality-of-life assessment in long-term glioblastoma survivors. J Neuro-Oncol 63(1):55–61

    Article  Google Scholar 

  145. Flechl B, Ackerl M, Sax C, Dieckmann K, Crevenna R, Gaiger A, Widhalm G, Preusser M, Marosi C (2012) Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors. J Neuro-Oncol 109(2):331–339

    Article  Google Scholar 

  146. Levin GT, Greenwood KM, Singh F, Tsoi D, Newton RU (2016) Exercise improves physical function and mental health of brain Cancer survivors: two exploratory case studies. Integr Cancer Ther 15(2):190–196

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, The University of Toledo Medical Center, 3000 Arlington Ave, Toledo, OH, 43614, USA

    Luke Mugge, Tarek R. Mansour, Megan Crippen, Yasaman Alam & Jason Schroeder

  2. The University of Toledo College of Medicine, 3000 Arlington Ave, Toledo, OH, 43614, USA

    Luke Mugge

  3. Department of Neurological Surgery, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, MI, 48202, USA

    Tarek R. Mansour

Authors
  1. Luke Mugge
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tarek R. Mansour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Megan Crippen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasaman Alam
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jason Schroeder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luke Mugge.

Ethics declarations

Conflict of interest

Fully understanding and affirming the importance of conflict disclosure, the authors of the enclosed manuscript affirm that they will faithfully report any and all conflicts that arise. Further, authors affirm that no conflicts of interest exist pertaining to personal or financial relationships, either public or private. The authors confirm that any changes in this status will require immediate disclosure to all appropriate parties.

Ethical approval

The manuscript enclosed, herein, was submitted with the full knowledge and approval of all listed authors. Each author contributed in a meaningful way to the production of this manuscript. The design and completion of this project was done in accordance with the highest institutional standards of ethics as outlined by the home institution. To the knowledge of the authors, the completion of this project causes neither infringement nor denial of any aspect of patient, physician, or organizational privacy or autonomy.

Informed consent

As a primary review, this manuscript involved no human subjects. No personal or medical information of any patient was discussed or disclosed as any part of this project. Any and all information found herein is fully available to the public domain and is attainable through basic and standard search modalities. As a review, this project did not require any consent from any third party or patient except from the authors who were involved in manuscript preparation. Consent from all authors was obtained prior to submission.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mugge, L., Mansour, T.R., Crippen, M. et al. Depression and glioblastoma, complicated concomitant diseases: a systemic review of published literature. Neurosurg Rev 43, 497–511 (2020). https://doi.org/10.1007/s10143-018-1017-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10143-018-1017-2

Keywords

Search

Navigation